RDEA3170 and Febuxostat Combination Study in Gout Subjects

Exclusion Criteria

• - Unable to take colchicine for gout flare prophylaxis.
• - History or suspicion of kidney stones.
• - Any gastrointestinal disorder that affects motility and/or absorption.
• - Unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants.
• - Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator.
• - Estimated creatinine clearance < 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the Screening period.
• - Taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing.
• - Unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.